- Home
- AUTL
as 05-13-2025 4:00pm EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 359.3M | IPO Year: | 2018 |
| Target Price: | $9.32 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $5.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $9,011,000 | Revenue Growth: | -14.16% |
| Revenue Growth (this year): | 277.74% | Revenue Growth (next year): | 221.89% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Autolus Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
5 days ago
Autolus Therapeutics PLC (AUTL) Q1 2025 Earnings Call Highlights: Strong US Launch and ...
GlobeNewswire
6 days ago
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
GuruFocus.com
7 days ago
Autolus Therapeutics PLC (AUTL) Q1 2025 Earnings Report Preview: What to Expect
TipRanks
18 days ago
Autolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRA
MT Newswires
19 days ago
Autolus Gets Conditional Marketing Authorization for Aucatzyl to Treat Relapsed Leukemia
GlobeNewswire
19 days ago
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
GlobeNewswire
20 days ago
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.